ENTtoday is the official news magazine of the Triological Society, and its two sister publications—The Laryngoscope and Laryngoscope Investigative Otolaryngology—are the official peer-reviewed journals. Here’s a look at the top 10 most-read articles from each journal from 2024.
Explore This Issue
December 2025
Variant Types of Preauricular Sinuses: Classifications, Clinical Presentation and Management
By Jinhui Chen, MD, Ping Zhou, MM, Jingjing Zuo, MD, Wei Ming, MD, Ting Huang, MM, and Zezhang Tao, MD (doi.org/10.1002/lary.31378)
We aim to increase surgeons’ awareness of the various types of preauricular sinuses (PAS) by summarizing our experience in diagnosing and treating these different types.
Washing Illness Away: A Systematic Review of the Impact of Nasal Irrigation and Spray on COVID‐19
By Karan Gandhi, MD, Freeman Paczkowski, BHSc, and Leigh Sowerby, MD, MHM, FRCSC (doi.org/10.1002/lary.31761)
Nasal irrigation is a common treatment for sinonasal disorders; however, it is unknown if it can reduce SARS-CoV-2 nasopharyngeal viral load. This systematic review investigated the efficacy of nasal irrigation with saline, povidone iodine, and intranasal corticosteroids at reducing SARS-CoV-2 NVL and transmissibility.
Effect of Hormone Replacement Therapy on Chronic Rhinosinusitis Management
By Kevin Herrera, BS, Miti Parikh, BA, Sahiti Vemula, BS, and Kevin Hur, MD (doi.org/10.1002/lary.31433)
The study investigates whether hormone replacement therapy impacts healthcare resource utilization in the management of chronic rhinosinusitis in older women.
Real‐World Adverse Events After Type 2 Biologic Use in Chronic Rhinosinusitis with Nasal Polyps
By Marisa Dorling, BSc, Juan C. Hernaiz-Leonardo, MD, Athenea Pascual, PhD, Arif Janjua, MD, FRCSC, Andrew Thamboo, MD, FRCSC, and Amin Javer, MD, FRCSC (doi.org/10.1002/lary.31305)
This study investigates the frequency and nature of adverse events related to type 2 biologic use in patients with chronic rhinosinusitis with nasal polyps (CRSwNP), including dupilumab and mepolizumab.
By Peter L. Friedland, MD, and Simon Tucker, PhD (doi.org/10.1002/lary.31430)
A Phase II trial was conducted to determine if nasal disinfection with a commercial Good Manufacturing Practice-manufactured 0.5% povidone-iodine nasal spray (Nasodine®) may be a useful adjunct in the management of COVID-19 by reducing viral shedding and preventing transmission of SARS-CoV-2. The aim was to confirm the results from a human single-dose pilot study by assessing repeated and frequent doses on nasal shedding of SARS-CoV-2 from adult subjects with confirmed COVID-19.
Impact of Biologics on Surgery in Chronic Rhinosinusitis with Polyps and Allergic Fungal Sinusitis
Leave a Reply